Emergency-Use Coverage (EUC)
How much of the portfolio enjoys the no-liability shield. Engineered scarcity and crisis keep the window open.
Formula
Thresholds & Bands
| Band | Range | State |
|---|---|---|
| Broad | ≥ 60 | ok |
| Partial | 30-60 | warn |
| Thin | < 30 | crit |
Why This Metric Matters
Emergency-Use Coverage quantifies the share of the Directorate's distributed pharmaceutical and device portfolio that operates under active emergency-use authorization, shielding Halcyon Biosciences from standard liability exposure. A high EUC means the organization can deploy experimental compounds, accelerated-schedule therapeutics, and restricted-build Halo firmware without bearing the legal and financial risk of conventional product liability. When EUC contracts, the Directorate faces the choice of halting deployment of uncovered assets or accepting unhedged liability, both of which constrain operational freedom. Maintaining broad coverage is therefore a strategic priority that directly enables the pace of the entire program.
Threshold Justification
The 60% broad-band floor ensures that a supermajority of the active portfolio -- including all BCL-3 and BCL-4 classified compounds -- remains within the liability shield at any given time. The 30% critical threshold was calibrated to the point at which the Liability Exposure metric historically transitions from manageable to material, based on actuarial models maintained by Legal and Compliance in coordination with PANACEA risk analytics.
Historical Context
EUC peaked at 85% during the initial crisis-authorization period, when the broad emergency declaration provided blanket coverage for the majority of the Directorate's portfolio. As individual authorizations began cycling through renewal and some were allowed to lapse by design, coverage settled to approximately 62% by mid-2025. The Directorate has since maintained EUC near the broad-band floor through a combination of rolling authorization renewals and the strategic introduction of new compounds timed to coincide with declared health emergencies.
Collection Method
Legal and Compliance maintains the authoritative registry of active emergency-use authorizations, mapping each authorization to the specific product lines and distribution volumes it covers. This registry is synchronized weekly with the Synaptic Data Fabric, where PANACEA computes the coverage percentage against the total distributed-asset inventory. The reported figure is updated every Monday at 06:00 UTC and represents the prior week's end-of-period state.
Known Failure Modes
The most significant failure mode is authorization-expiry lag, in which an emergency-use authorization has technically lapsed but the registry has not yet been updated, producing an inflated EUC reading that conceals active liability exposure. Conversely, newly issued authorizations may take several business days to propagate through Legal's documentation pipeline into the Synaptic Data Fabric, temporarily depressing the metric below its true value. Coverage calculations can also be distorted when product-line boundaries are redefined (e.g., through formulation changes or rebranding) without corresponding updates to the authorization mapping, creating orphaned assets that fall outside any active shield.